FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa — January 6, 2026 — Leads & Copy — Syncromune® Inc., a clinical-stage biopharmaceutical company focused on developing SYNC-T™, an in situ platform combination immunotherapy optimized for solid tumor cancers, has appointed Stephen P. Dale, M.D., as Chief Medical Officer.
Dr. Dale brings over 20 years of global oncology research and development leadership to Syncromune. His experience includes early- and late-stage clinical development and translational strategy, contributing to multiple regulatory approvals. He has guided programs through pivotal trial design, first-in-class dose optimization, and IND-enabling studies, aligning with FDA and EMA guidance.
Before joining Syncromune, Dr. Dale was Head of R&D and Chief Medical Officer at Kura Oncology. He also held senior oncology R&D and clinical leadership roles at Kyowa Kirin and AstraZeneca, leading global development programs across various tumors, immuno-oncology, precision oncology, and rare diseases. He earned his Doctor of Medicine and MBChB degrees from the University of Manchester Medical School.
As Chief Medical Officer, Dr. Dale will lead the clinical development of SYNC-T, provide strategic and medical oversight for Syncromune’s pipeline, and shape the company’s clinical, regulatory, and translational roadmap.
Chuck Link, M.D., Co-Founder and Executive Chairman at Syncromune, stated that the company’s priority is to develop therapies that significantly improve the lives of patients facing challenging cancers. He added that Dr. Dale’s perspective and patient-focused approach will ensure programs prioritize safety and impact as clinical objectives advance.
Eamonn Hobbs, Co-Founder, President, and Chief Executive Officer of Syncromune, noted Dr. Dale’s oncology experience and leadership in advancing therapies through clinical development. He said that his expertise will be invaluable as SYNC-T Therapy SV-102 progresses through Phase 2 and expands the platform’s potential across solid tumors.
Dr. Dale expressed his honor in joining Syncromune, stating that the company’s vision aligns with his patient-centered approach. He said he is eager to accelerate therapies that offer new possibilities for patients with limited treatment options.
Syncromune is developing SYNC-T, a platform immunotherapy designed to address unmet medical needs in metastatic solid tumor cancers. SYNC-T is an in situ personalized cancer therapy engineered to synchronize the location of three components critical to T cell activation and an anti-tumor immune response. Its lead candidate, SYNC-T Therapy SV-102 for metastatic castration-resistant prostate cancer, is being evaluated in the LEGION-100 Phase 2 trial.
Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
Danielle Hobbs
Syncromune, Inc.
EVP, Marketing & Commercial Strategy
media@syncromune.com
Source: Syncromune
